TY  - GEN
AU  - Fontán-Vela, Mario
AU  - Hernando Sebastian, Victoria
AU  - Olmedo, Carmen
AU  - Coma, Ermengol
AU  - Martínez, Montse
AU  - Moreno-Perez, David
AU  - Lorusso, Nicola
AU  - Vázquez Torres, María
AU  - Barbas del Buey, José Francisco
AU  - Roig-Sena, Javier
AU  - Pastor, Eliseo
AU  - Galmés Truyols, Antònia
AU  - Artigues Serra, Francisca
AU  - Sancho Martínez, Rosa María
AU  - Latasa Zamalloa, Pello
AU  - Pérez Martínez, Olaia
AU  - Vázquez Estepa, Ana
AU  - García Rojas, Amós José
AU  - Barreno Estévez, Ana Isabel
AU  - Sánchez-Migallón Naranjo, Alonso
AU  - Pérez Martín, Jaime Jesús
AU  - Peces Jiménez, Pilar
AU  - Morales Romero, Raquel
AU  - Castilla, Jesús
AU  - García Cenoz, Manuel
AU  - Huerta Huerta, Marta
AU  - Boone, An Lieve Dirk
AU  - Macías Ortiz, María José
AU  - Álvarez Río, Virginia
AU  - Rodríguez Recio, María Jesús
AU  - Merino Díaz, María
AU  - Berradre Sáenz, Belén
AU  - Villegas-Moreno, María Teresa
AU  - Limia, Aurora
AU  - Diaz Franco, Asuncion
AU  - Monge Corella, Susana
AU  - Spanish MPOX vaccine effectiveness study group
AU  - Jarrin-Vera, Inmaculada
PY  - 2024
DO  - 10.1093/cid/ciad645
SN  - 1058-4838
UR  - http://hdl.handle.net/20.500.12105/16837
AB  - Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure...
LA  - eng
PB  - Oxford University Press
KW  - mpox
KW  - Monkeypox
KW  - Vaccine effectiveness
KW  - MVA-BN vaccine
KW  - Pre-exposure prophylaxis
TI  - Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study
TY  - research article
ER  -